Quantcast

Latest OncoGenex Pharmaceuticals Inc. Stories

2010-08-10 05:00:00

BOTHELL, WA, and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that the Company has appointed Mr. David V. Smith to its board of directors. Mr. Smith brings to the board substantial financial expertise in financial controls, analytics and process. Having served in executive financial positions for multi-billion dollar life sciences companies, Mr. Smith also adds deep experience in the design and implementation of strategic growth...

2010-08-05 15:01:00

Conference Call on Thursday, August 5, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA and VANCOUVER, Aug. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010. The Company reported net income of $0.2 million for the quarter ended June 30, 2010. Net loss before income taxes for the...

2010-07-29 05:00:00

BOTHELL, WA and VANCOUVER, July 29 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter financial results will be released on Thursday, August 5, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing...

2010-06-21 05:00:00

BOTHELL, WA, and VANCOUVER, June 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between...

2010-06-07 08:00:00

Results Presented at ASCO 2010 Annual Meeting Confirm Acceptable Safety Profile and Evidence of Biological Activity Including Declines in Circulating Tumor Cells and Reductions in Tumor Markers BOTHELL, WA, and VANCOUVER, June 7 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various...

2010-06-03 05:00:00

BOTHELL, WA and VANCOUVER, June 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 9th Annual Needham Healthcare Conference on June 10 at 10:40 a.m. ET at the New York Palace Hotel in New York City. A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. A webcast replay will be available...

2010-05-13 15:00:00

BOTHELL, WA,and VANCOUVER, May 13 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's President and Chief Executive Officer, will present at the 6th Annual Rodman and Renshaw Global Healthcare Conference on May 17 at 4:30 p.m. BST (11:30 a.m. EDT) at the Grosvenor House Hotel in London, UK. A live webcast will be available through the Investor Relations page of the OncoGenex Web site at http://ir.oncogenex.com. A webcast...

2010-05-06 15:01:00

Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, May 6 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three months ended March 31, 2010 and reviewed the Company's highlights for the first quarter of 2010. Financial Results Revenue for the first quarter ended March 31, 2010 was $4.7 million, of which $1.9 million consisted of partial...

2010-04-29 05:00:00

BOTHELL, WA, and VANCOUVER, April 29 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter financial results will be released on Thursday May 6, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. EDT that afternoon. Management will discuss the company's first quarter results and provide an update on the business and product pipeline. To access the webcast, log on to the Investor Relations page...

2010-03-24 05:00:00

BOTHELL, WA and VANCOUVER, BC, March 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), announced today that the Company has appointed Dr. Jack Goldstein and Ms. H. Stewart Parker to its board of directors. In addition, Dr. Martin Mattingly has agreed to stand for election at the Company's upcoming Annual General Meeting. Dr. Goldstein joins the board as chairman. The new board members add substantial pharmaceutical industry experience having held or currently holding...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.